Biosynex (ALBIO) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.160x

Based on the latest financial reports, Biosynex (ALBIO) has a cash flow conversion efficiency ratio of -0.160x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.07 Million ≈ $-8.26 Million USD) by net assets (€44.31 Million ≈ $51.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALBIO days of operational coverage to measure how many days the company can operate on defensive assets alone.

Biosynex - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Biosynex's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Biosynex Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biosynex ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Lena Lighting S.A.
WAR:LEN
-0.024x
Wetouch Technology Inc. Common Stock
NASDAQ:WETH
0.004x
Sub Sri Thai Public Company Limited
BK:SST
0.054x
MyTech Group Bhd
KLSE:7692
0.134x
VOLT RESOURCES LTD
F:R8L
N/A
Clean Seas Seafood Limited
F:C7S
-0.016x
Ovanti Ltd
AU:OVT
-0.245x
Putprop Ltd
JSE:PPR
0.010x

Annual Cash Flow Conversion Efficiency for Biosynex (2008–2024)

The table below shows the annual cash flow conversion efficiency of Biosynex from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Biosynex (ALBIO) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €80.50 Million
≈ $94.11 Million
€-10.12 Million
≈ $-11.83 Million
-0.126x -61.91%
2023-12-31 €124.31 Million
≈ $145.34 Million
€-9.65 Million
≈ $-11.29 Million
-0.078x -361.86%
2022-12-31 €166.76 Million
≈ $194.96 Million
€4.95 Million
≈ $5.78 Million
0.030x -95.47%
2021-12-31 €167.81 Million
≈ $196.18 Million
€109.83 Million
≈ $128.41 Million
0.655x +37.14%
2020-12-31 €66.29 Million
≈ $77.50 Million
€31.64 Million
≈ $36.99 Million
0.477x +1213.25%
2019-12-31 €30.38 Million
≈ $35.52 Million
€1.10 Million
≈ $1.29 Million
0.036x +127.67%
2018-12-31 €29.26 Million
≈ $34.21 Million
€467.12K
≈ $546.11K
0.016x -4.82%
2017-12-31 €28.91 Million
≈ $33.80 Million
€484.82K
≈ $566.81K
0.017x -16.59%
2016-12-31 €24.36 Million
≈ $28.48 Million
€489.91K
≈ $572.75K
0.020x -7.96%
2015-12-31 €21.13 Million
≈ $24.70 Million
€461.66K
≈ $539.73K
0.022x +110.31%
2009-12-31 €-341.55K
≈ $-399.30K
€72.40K
≈ $84.65K
-0.212x -117.67%
2008-12-31 €-153.74K
≈ $-179.73K
€-184.44K
≈ $-215.63K
1.200x --

About Biosynex

PA:ALBIO France Medical Devices
Market Cap
$19.09 Million
€16.33 Million EUR
Market Cap Rank
#25864 Global
#428 in France
Share Price
€0.89
Change (1 day)
-0.45%
52-Week Range
€0.48 - €1.57
All Time High
€25.28
About

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more